Effect of Using Bitter Melon, Blueberries and Cranberries on HbA1c and Diabetes Symptom Levels
NCT ID: NCT07233460
Last Updated: 2025-11-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
120 participants
INTERVENTIONAL
2024-02-06
2024-05-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Blueberry Dry Powder on Glycemic Status in Subjects With Prediabetes
NCT02023320
Explore the Effect of Bitter Melon Peptides on Glycemic Control and Metabolic Indicators in Diabetic Patients
NCT06970834
Effects of Bitter Melon on Cardiometabolic Health
NCT05540405
Dog-rose, Cranberry Leaves, Cranberry Berries, Alfalfa, Fenugreek, Lemon Beebrush, Urtica and Sumac in Diabetes Mellitus
NCT05700513
Acute Study of Anthocyanin-rich Bilberry and Polyphenol-rich Apple Extracts on Postprandial Glycaemic Response
NCT04004182
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study, conducted with four groups (bitter melon, blueberry, cranberry, and control), included 120 individuals diagnosed with T2DM. Individuals in the experimental group used 10g of powdered extract daily for 12 weeks, while those in the control group used nothing. The 'Patient Information Form' and 'Diabetes Symptoms Checklist Scale' were administered before the start of the study (pre-test/week 0) and at the end (post-test/week 12), and the venous blood value of the Hemoglobin A1c test (HbA1c) was measured.
In the experimental groups (bitter melon, blueberry, cranberry), after 12 weeks of treatment, statistically significant decreases were observed in HbA1c, the total score and all Subdimensions scores of the 'Diabetes Symptoms Checklist Scale', weight, and BMI compared to the control group; while in the control group, there was a significant increase in all parameters except HbA1c (p\<0.05). Although there was no difference between the experimental (bitter melon, blueberry, cranberry) groups in the intergroup measurements, HbA1c, the total mean scores of the Diabetes Symptom Checklist Scale, weight, and BMI were found to be significantly lower than in the control group (p\<0.05).
Bitter melon, blueberry, and cranberry powder extracts were found to be equally effective in reducing HbA1c, diabetes symptoms, weight, and BMI in T2DM patients. The lack of difference in efficacy between the three extracts in terms of glycemic and symptom levels suggests that these three natural products can be considered equivalent therapeutic options in the complementary treatment of T2DM.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Bitter melon Group
Before starting the study (pre-test/week 0), all group participants first completed the "Patient Information Form" and the "Diabetes Symptom Checklist Scale," and their HbA1c venous blood values were measured. At the end of the study (post-test/12th week), the "Diabetes Symptom Checklist Scale" was administered again to individuals in the three groups, and their HbA1c venous blood values were measured. In addition, telephone follow-up was conducted to determine whether the individuals had used the powdered extracts completely for 12 weeks.
Bitter Melon Group
Patients who voluntarily used bitter melon powder extract continued to consume 1 teaspoon (10 g total) of powdered extract mixed with yogurt or water twice a day (morning and evening) for 12 weeks.
Blueberry Group
Before starting the study (pre-test/week 0), all group participants first completed the "Patient Information Form" and the "Diabetes Symptom Checklist Scale," and their HbA1c venous blood values were measured. At the end of the study (post-test/12th week), the "Diabetes Symptom Checklist Scale" was administered again to individuals in the three groups, and their HbA1c venous blood values were measured. In addition, telephone follow-up was conducted to determine whether the individuals had used the powdered extracts completely for 12 weeks.
Blueberry Group
Patients who voluntarily used bitter blueberry powder extract continued to consume 1 teaspoon (10 g total) of powdered extract mixed with yogurt or water twice a day (morning and evening) for 12 weeks.
Cranberry Group
Before starting the study (pre-test/week 0), all group participants first completed the "Patient Information Form" and the "Diabetes Symptom Checklist Scale," and their HbA1c venous blood values were measured. At the end of the study (post-test/12th week), the "Diabetes Symptom Checklist Scale" was administered again to individuals in the three groups, and their HbA1c venous blood values were measured. In addition, telephone follow-up was conducted to determine whether the individuals had used the powdered extracts completely for 12 weeks.
Cranberry Group
Patients who voluntarily used cranberry powder extract continued to consume 1 teaspoon (10 g total) of powdered extract mixed with yogurt or water twice a day (morning and evening) for 12 weeks.
Control Group
Before starting the study (pre-test/week 0), all group participants first completed the "Patient Information Form" and the "Diabetes Symptom Checklist Scale," and their HbA1c venous blood values were measured. At the end of the study (post-test/12th week), the "Diabetes Symptom Checklist Scale" was administered again to individuals in the three groups, and their HbA1c venous blood values were measured.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bitter Melon Group
Patients who voluntarily used bitter melon powder extract continued to consume 1 teaspoon (10 g total) of powdered extract mixed with yogurt or water twice a day (morning and evening) for 12 weeks.
Blueberry Group
Patients who voluntarily used bitter blueberry powder extract continued to consume 1 teaspoon (10 g total) of powdered extract mixed with yogurt or water twice a day (morning and evening) for 12 weeks.
Cranberry Group
Patients who voluntarily used cranberry powder extract continued to consume 1 teaspoon (10 g total) of powdered extract mixed with yogurt or water twice a day (morning and evening) for 12 weeks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Volunteering to participate in the study,
* Being conscious and able to communicate,
* Having been diagnosed with T2DM at least 3 months prior and currently using oral antidiabetic medication,
* Be using one of the following powder extracts-bitter melon, blueberry, or cranberry-for the first time as a complementary treatment upon a physician's recommendation and be on the first day of use,
* Not taking any other medications that affect blood sugar,
* No allergy to bitter melon, blueberry, or cranberry,
* Not engaging in exercise,
* Taking 10g of bitter melon, blueberry, or cranberry powder extract daily.
* Having previously received complementary therapy for DM, or having hearing loss.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Karadeniz Technical University
OTHER
Hatice Demirağ, Ph.D
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hatice Demirağ, Ph.D
Assistant Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hatice Demirağ
Role: PRINCIPAL_INVESTIGATOR
Study Principal Investigator Gümüşhane Universıty
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Gümüşhane University
Gümüşhane, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RCS05022024
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.